A cell-targeted chemotherapeutic nanomedicine strategy for oral squamous cell carcinoma therapy

Wang, Zhiqi; Li, Kai; Huo, Zongwei; Li, Xiaochen; Wang, Min; Liu, Ping; Pang, Bo; Wang, Shijiang

doi:10.1186/s12951-015-0116-2

Cited by 49 publications

(42 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Ligand-decorated cancer-targeted CDDP-loaded PLGA-PEG/NR7 NPs were formulated by Wang et al [23]. NR7 peptide is based on alignment of the tripeptide motif with the EGF binding domain.…”

Section: Cddpmentioning

confidence: 99%

Nanomedicine, an emerging therapeutic strategy for oral cancer therapy

et al. 2018

View full text Add to dashboard Cite

Oral cavity and oropharyngeal carcinomas (oral cancer) represents a significant cause of morbidity and mortality. Despite efforts in improving early diagnosis and treatment, the 5-year survival rate of advanced stage of the disease is less than 63%. The field of nanomedicine has offered promising diagnostic and therapeutic advances in cancer. Indeed, several platforms have been clinically approved for cancer therapy, while other promising systems are undergoing exploration in clinical trials. With its ability to deliver drugs, nucleic acids, and MRI contrast agents with high efficiency, nanomedicine platforms offer the potential to improve drug efficacy and tolerability. The aim of the present mini-review is to summarize the current preclinical status of nanotechnology systems for oral cancer therapy. The nanoplatforms for delivery of chemopreventive agents presented herein resulted in significantly higher anti-tumor activity than free forms of the drug, even against a chemo-resistant cell line. Impressive results have also been obtained using nanoparticles to deliver chemotherapeutics, resulting in reduced toxicity both in vitro and in vivo. Nanoparticles have also led to improvements in efficacy of photodynamic therapies through the development of targeted magnetic nanoparticles. Finally, gene therapy using nanoparticles demonstrated promising results specifically with regards to inhibition of gene expression. Of the few in vivo studies that have been reported, many of these used animal models with several limitations, which will be discussed herein. Lastly, we will discuss several future perspectives in oral cancer nanoparticle-based therapy and the development of appropriate animal models, distinguishing between oral cavity and oropharyngeal carcinoma.

show abstract

“…Ligand-decorated cancer-targeted CDDP-loaded PLGA-PEG/NR7 NPs were formulated by Wang et al [23]. NR7 peptide is based on alignment of the tripeptide motif with the EGF binding domain.…”

Section: Cddpmentioning

confidence: 99%

Nanomedicine, an emerging therapeutic strategy for oral cancer therapy

et al. 2018

View full text Add to dashboard Cite

show abstract

“…Recently, nanoparticles (NPs) have made inroads in the therapy of different types of squamous cell carcinoma (SCC), which is an epithelial malignancy, and the majority of the cases comprise non-melanoma skin cancer, head and neck cancer, oral and esophageal cancer and non-small cell lung cancer. 1 Surgery, radiation therapy, chemotherapy or combination of these is used to deal with the serious threats of malignancy. Photodynamic therapy is also playing an important role, specifically in superficial SCC, but oral cancer and esophageal cancer need the intervention of localized therapy on exposed lesions.…”

Section: Introductionmentioning

confidence: 99%

Curcuminoid-loaded poly(methyl methacrylate) nanoparticles for cancer therapy

Sahu¹,

Solanki²,

Mitra³

2018

IJN

View full text Add to dashboard Cite

Curcuminoids (Curs), oleoresins from Curcuma longa L., have known anticarcinogenic and anti-inflammatory properties, but high toxicity, poor aqueous solubility and susceptibility to degradation in body fluids are deterrents to their clinical administration. Poly(methyl methacrylate) nanoparticles (PMMA-NPs) are biocompatible and resilient and can entrap hydrophobic drugs. The present investigation is related to solubilizing Curs by incorporating them in these nanoparticles (NPs) and is related to a study comparing the anticarcinogenic effect of drug-loaded NPs with free Cur using lung cancer (A549) cell line. Freshly extracted oleoresins were post loaded in PMMA-NPs prepared using emulsion polymerization. The presence of the three components of oleoresins was confirmed by thin-layer chromatography. The size and morphology of void and loaded NPs were determined by dynamic light scattering, scanning electron microscopy and transmission electron microscopy. The NPs were spherical with diameters of 192.66±5 nm (void) and 199.16±5 nm (loaded). Drug loading and encapsulation efficiency were 6% and 93%, respectively. From the Fourier transform infrared spectroscopy spectra, the characteristic absorption vibration of poly(methyl methacrylate) and the bands at 1,383, 1,233 and 962 cm−1 for Cur moiety were observed. Drug release up to 10 days was estimated in buffer, saline and serum. The highest release of ~55% in ~3 days was noted in buffer that exhibited the highest bioavailability. The in vitro anticancer activity of loaded drug was evaluated up to 72 hours by MTT assay using A549 cell line. Cellular uptake of dye-loaded NPs was visualized within 30 minutes of incubation. The results revealed that the dose- and time-dependent cell death in case of loaded PMMA-NPs was comparable to that of free Cur. According to the study, the drug-loaded PMMA-NPs appear to be highly suitable for effective, localized and safe chemotherapy.

show abstract

“…Oral squamous cell carcinoma (OSCC) is among the most frequent pathological types of oral cancer (3,4). Despite recent breakthroughs in surgical, chemoradiotherapeutic and biological treatments, as well as molecular targeting therapy, the long-term therapeutic impact remains poor (5,6). Additionally, the clinical signs of ~2/3 patients with OSCC in the early stages are not distinguishable as the disease is typically diagnosed in the advanced stages (7).…”

Section: Introductionmentioning

confidence: 99%

Overexpression of MARCKS indicates a poor prognosis of oral squamous cell carcinoma

Xia

Xue

et al. 2018

Oncol Lett

View full text Add to dashboard Cite

Myristoylated alanine-rich C kinase substrate (MARCKS) is a protein kinase C substrate functioning in different physiological and pathological mechanisms. Previous studies have suggested that MARCKS is capable of influencing tumorigenesis and progression. However, a limited number of studies are available regarding the role of MARCKS in oral squamous cell carcinoma (OSCC). The present study primarily examined MARCKS expression in the OSCC tissues. Furthermore, increased expression of MARCKS was confirmed in the majority of OSCC tissues. Increased MARCKS expression was correlated with more advanced tumor stages, lymphatic metastasis and a poorer overall patient survival. Further molecular mechanistic examinations revealed that downregulated MARCKS expression inhibited the proliferation and migration of OSCC cells through interruption of MARCKS expression. In addition, the present study demonstrated that MARCKS aggravated OSCC progression via the phosphoinositide 3-kinase/protein kinase B pathway. Accordingly, the present study considered MARCKS to be a promoter of OSCC tumorigenesis and progression, with the potential utility as a biomarker of a poor prognosis.

show abstract

A cell-targeted chemotherapeutic nanomedicine strategy for oral squamous cell carcinoma therapy

Cited by 49 publications

References 23 publications

Nanomedicine, an emerging therapeutic strategy for oral cancer therapy

Nanomedicine, an emerging therapeutic strategy for oral cancer therapy

Curcuminoid-loaded poly(methyl methacrylate) nanoparticles for cancer therapy

Overexpression of MARCKS indicates a poor prognosis of oral squamous cell carcinoma

Contact Info

Product

Resources

About